Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPulmonologyHealthplan Upper Ohio Valley iNO Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentHealth Plan of the Upper Ohio Valley, Inc.Policy N/A

    Inhaled Nitric Oxide (iNO)

    Customize your policy alerts

    Sign up for all healthplanofupperohiovalley policy alerts

    Know when healthplanofupperohiovalley releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity coverage and coding for inhaled nitric oxide (iNO) therapy services. It applies to providers and facilities serving the plan's Commercial, Mountain Health Trust, PEIA, and Self-Funded lines of business.

    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley, Inc.
    PolicyInhaled Nitric Oxide (iNO)
    Policy CodePolicy N/A
    Change TypeMaterial clinical and coverage update
    Effective Date7/29/2024
    Next Review Date7/29/2025
    Key ActionSubmit every iNO therapy request for medical-necessity review and medical-director comment.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added medical-necessity criteria for using iNO to assess pulmonary vasoreactivity in individuals with pulmonary hypertension.

    The policy added traumatic brain injury to the list of iNO indications considered not medically necessary and non-covered.

    The policy added peer-reviewed-literature language to the statement that iNO therapy outside the listed criteria is experimental or investigational.

    The policy added a purpose section, definitions, diagnosis codes, and updated references and formatting.

    3Covered iNO indication categories
    ≥34 weeksMinimum gestational age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    15
    Non-covered indication categories
    2Listed procedure codes
    Medical directorRequired review

    Medical Necessity and Non-Covered Uses

    Medically necessary indications

    Requests meeting ANY of the following indications may be considered medically necessary. All requests require medical-necessity review and comment by a medical director.

    Covered indications

    • Neonatal hypoxic respiratory failure or PPHN

      • Underlying neonatal indication: Hypoxic respiratory failure or echocardiographic evidence of PPHN.
      • Required neonatal conditions: The neonate is at least 34 weeks gestation; congenital diaphragmatic hernia is absent; and conventional therapies, including high concentrations of oxygen, hyperventilation, high-frequency ventilation, induction of alkalosis, neuromuscular blockade, and sedation, have failed or are expected to fail.≥34 weeks gestation
    • Postoperative pulmonary hypertensive crisis: Post-operative management of pulmonary hypertensive crisis in an infant or child with congenital heart disease.
    • Diagnostic pulmonary vasoreactivity assessment: Diagnostic assessment of pulmonary vasoreactivity in an individual with pulmonary hypertension.

    Not medically necessary and non-covered indications

    iNO therapy that does not meet the covered criteria is considered experimental/investigational because safety and efficacy have not been established by peer-reviewed literature. The following uses are considered not medically necessary and non-covered.

    Non-covered or experimental indications

    • Acute respiratory and pulmonary conditions: Acute bronchiolitis; acute hypoxemic respiratory failure in children who do not meet the covered criteria or in adults; acute pulmonary embolism; or acute respiratory distress syndrome or acute lung injury, including COVID-19-related ARDS.
    • Neonatal and transplant uses: Prevention of bronchopulmonary dysplasia in preterm infants without hypoxic respiratory failure; prevention of ischemia-reperfusion injury or acute rejection following lung transplantation; or treatment of congenital diaphragmatic hernia.
    • Other excluded uses: Adjunctive treatment of malaria; adult pulmonary arterial hypertension; respiratory failure in preterm newborns under 35 weeks gestational age when used for early rescue during the first three days of life, after the first three days of life because of increased bronchopulmonary dysplasia risk, or routine prophylaxis during respiratory support; treatment of sickle cell vaso-occlusive crisis or acute chest syndrome; treatment of Mycobacterium or Pseudomonas aeruginosa infections in persons with cystic fibrosis; treatment of pulmonary hypertension associated with pulmonary fibrosis; treatment of right heart failure after hemorrhagic shock and trauma pneumonectomy; or treatment of traumatic brain injury.

    Inhaled nitric oxide (iNO) is non-covered for acute bronchiolitis and for acute hypoxemic respiratory failure in adults or in children who do not meet the policy’s covered criteria.

    iNO therapy that does not meet a covered indication is considered experimental/investigational because its safety and efficacy have not been established by peer-reviewed literature.

    Each indication listed under the policy’s contraindications, exclusions, and experimental/investigational uses is considered not medically necessary and non-covered. These uses include acute pulmonary embolism; ARDS or acute lung injury, including COVID-19-related ARDS; prevention of bronchopulmonary dysplasia in preterm infants without hypoxic respiratory failure; prevention of ischemia-reperfusion injury or acute rejection after lung transplantation; adjunctive treatment of malaria; adult pulmonary arterial hypertension; specified respiratory-failure uses in preterm newborns under 35 weeks’ gestation; sickle cell vaso-occlusive crisis or acute chest syndrome; cystic-fibrosis-associated Mycobacterium or Pseudomonas aeruginosa infection; congenital diaphragmatic hernia; pulmonary hypertension associated with pulmonary fibrosis; right heart failure after hemorrhagic shock and trauma pneumonectomy; and traumatic brain injury.

    Procedure and Diagnosis Codes

    Procedure CodesCPT
    94363Pharmacologic agent administration (eg, inhaled nitric oxide, intravenous infusion of nitroprusside, dobutamine, milrinone, or other agent) including assessing hemodynamic measurements before, during, after and repeat pharmacologic agent administration, when performed (List separately in addition to code for primary procedure)
    94799Unlisted pulmonary service or procedure
    Covered Diagnosis CodesICD-10Covered
    I27.0Primary pulmonary hypertension
    I27.20-I27.29Other secondary pulmonary hypertension
    P07.20-P07.39Disorders of newborn related to short gestation
    P22.0Respiratory distress syndrome of newborn
    P28.5Respiratory failure of newborn
    P29.30-P29.38Persistent fetal circulation
    P36.0-P36.9Bacterial sepsis of newborn
    P84Other problems with newborn [birth asphyxia]
    P91.60-P91.63Hypoxic ischemic encephalopathy [HIE]
    Q33.1Accessory lobe of lung
    1–10 of 17
    1/2
    Pulmonary artery pressure
    ThresholdAt least 25 mm Hg at rest
    Measurement methodMeasured during right heart catheterization
    Defined conditionPulmonary hypertension is defined by a mean pulmonary artery pressure meeting this threshold
    Neonatal gestational age
    Minimum gestational ageAt least 34 weeks gestation
    Applicable populationNeonates
    Covered context

    Authorization and Documentation Requirements

    Prior Authorization

    Medical Director Review Required

    All requests for inhaled nitric oxide (iNO) therapy services require medical-necessity review and comment by a medical director before coverage determination.

    Documentation Required

    Medical Necessity Documentation

    The medical record must include documentation supporting the applicable medical-necessity criteria. Records are subject to post-payment audit by the Health Plan of the Upper Ohio Valley at any time under the provider agreement.

    • Document the clinical indication and supporting findings for iNO therapy.
    • Ensure records are available for post-payment review.
    Documentation Required

    Clinical Background

    Inhaled nitric oxide is a lipophilic gas absorbed across pulmonary membranes in ventilated lung regions. After inhalation, it selectively produces pulmonary vasodilation while leaving systemic vascular resistance unaffected. The policy addresses its use primarily for neonatal hypoxic respiratory failure or persistent pulmonary hypertension of the newborn, postoperative pulmonary hypertensive crisis, and diagnostic assessment of pulmonary vasoreactivity.

    Key Terms

    Nitric oxide
    FormA lipophilic gas
    AbsorptionReadily absorbed across pulmonary membranes in the ventilated lung after inhalation
    Pulmonary effectSelectively induces pulmonary vasodilation
    Systemic effectLeaves systemic vascular resistance unaffected
    Pulmonary hypertension
    Vascular changePulmonary blood vessels develop an increased amount of muscle in their walls
    Effect on vesselsThe arteries in the lungs can narrow
    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley, Inc.
    PolicyInhaled Nitric Oxide (iNO)
    Policy CodePolicy N/A
    Change TypeMaterial clinical and coverage update
    Effective Date7/29/2024
    Next Review Date7/29/2025
    Key ActionSubmit every iNO therapy request for medical-necessity review and medical-director comment.
    SourceLink
    On This Page
    Medical Necessity and Non-Covered UsesProcedure and Diagnosis CodesAuthorization and Documentation RequirementsClinical BackgroundKey Terms
    <35 weeks gestational age for the specified preterm uses
    Neonatal hypoxic respiratory failure or echocardiographic evidence of persistent pulmonary hypertension of the newborn

    Neonatal Clinical Documentation

    For neonatal requests, document the criteria supporting treatment, including gestational age, congenital diaphragmatic hernia status, and the required respiratory or echocardiographic findings.

    • Gestational age of at least 34 weeks when the neonatal criterion is used.
    • Absence or presence of congenital diaphragmatic hernia, as applicable.
    • Hypoxic respiratory failure or echocardiographic evidence of persistent pulmonary hypertension of the newborn (PPHN).
    • Failure or expected failure of conventional therapies, when applicable, including high concentrations of oxygen, hyperventilation, high-frequency ventilation, induction of alkalosis, neuromuscular blockade, and sedation.
    Denial Risk

    Non-Covered and Experimental/Investigational Uses

    Requests that do not meet the covered criteria are considered experimental/investigational or not medically necessary and therefore non-covered. The following uses are explicitly non-covered.

    • Acute bronchiolitis.
    • Acute hypoxemic respiratory failure in children who do not meet the applicable medical-necessity criteria, and acute hypoxemic respiratory failure in adults.
    • Acute pulmonary embolism.
    • Acute respiratory distress syndrome or acute lung injury, including COVID-19-related ARDS.
    • Prevention of bronchopulmonary dysplasia in preterm infants without hypoxic respiratory failure.
    • Prevention of ischemia-reperfusion injury or acute rejection following lung transplantation.
    • Adjunctive treatment of malaria.
    • Pulmonary arterial hypertension in adults.
    • Respiratory failure in preterm newborns younger than 35 weeks' gestational age when used as early rescue within the first three days of life, after the first three days because of increased risk of bronchopulmonary dysplasia, or as routine prophylaxis in those requiring respiratory support.
    • Treatment of vaso-occlusive crises or acute chest syndrome in sickle cell disease.
    • Treatment of Mycobacterium or Pseudomonas aeruginosa infections in persons with cystic fibrosis.
    • Treatment of persons with congenital diaphragmatic hernia.
    • Treatment of pulmonary hypertension associated with pulmonary fibrosis.
    • Treatment of right heart failure after hemorrhagic shock and trauma pneumonectomy.
    • Treatment of traumatic brain injury.
    • Any other iNO therapy that does not meet the policy's covered indications.
    Effect on circulationBlood does not flow as well as it should, resulting in less oxygen in the blood